Berberine is a Chinese herbal medicine extracted from rhizoma coptidis that functions to improve insulin resistance, hyperlipidemia, hepatosteatosis and inflammation. Berberine can modify the activity of cell metabolism and signaling pathways by regulating expression of genes. However, the roles and effects of differential microRNA (miRNA) expression induced by berberine treatment are largely unexplored. It is believed that miRNAs expression modified by berberine contributes to its therapeutic effects to diseases such as hepatosteatosis and non-alcoholic fatty liver disease. By identifying novel miRNAs and their putative gene targets associated with abnormal hepatic lipid deposition, the underlying mechanism of these diseases could be established and effective therapies against the diseases could be developed. Here, we used the immortalized hepatocyte cell line MIHA as a model to study the effect of berberine on global miRNA expression profile of hepatocytes. Global miRNA expression levels were measured in berberine-treated MIHA cells by quantitative reverse transcription PCR miRNA panel, and the potential berberine regulated miRNAs were then validated in MIHA and HepG2 cells. MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments. Gene expression microarray showed that berberine upregulated Early Growth Response 1 (EGR1) level which functioned to transactivate miR-373 expression. Subsequently, we showed that upregulation of miR-373 depleted its target gene AKT serine/threonine kinase 1 (AKT1) mRNA level, which led to the inhibition of AKT-mTOR-S6K signaling pathway in hepatocytes that was critical in the development of hepatosteatosis. Study of the therapeutic effect of manipulating miR-373 against abnormal lipid deposition in liver is warranted.
Introduction
Berberine is a Chinese herbal medicine extracted from rhizoma coptidis. Studies showed that berberine had multiple pharmacological effects to treat conditions such as abnormal lipid deposition in human body including hyperlipidemia (Brusq et al., 2006) and hepatosteatosis . Berberine improved insulin resistance to treat diabetes (Kong et al., 2009 ) and non-alcoholic fatty liver disease (NAFLD) (Chang et al., 2010; Zhang et al., 2008) . Furthermore, berberine showed anti-inflammatory effect that alleviated the pathogenesis of NAFLD (Guo et al., 2016) . However, the underlying mechanisms of berberine in regulating lipid deposition in liver are not fully understood, hence identification of important players regulated by berberine can improve our understanding of the therapeutic effect of berberine and the critical events during the development of liver disorders such as hepatosteatosis.
The abilities of berberine to modify metabolism and cell signaling contribute to its therapeutic effect against abnormal lipid level in human tissues and organs. Berberine activated AMPK to inhibit triglyceride and cholesterol synthesis (Srivastava et al., 2012) . It also increased the oxidation of fatty acid by elevating fatty acid oxidation genes Yang et al., 2011; Xu et al., 2014; Zhang et al., 2014; Xue et al., 2015) in liver and reduced the expression of lipogenic genes (Huang et al., 2006; Ge et al., 2011; Xue et al., 2015) . Berberine also exhibited therapeutic effect on dyslipidemia through upregulating low density lipoprotein receptor (LDLR) post-transcriptionally (Kong et al., 2004) . These evidences suggest that berberine could modulate gene expressions to ameliorate abnormal lipid deposition in human tissues.
Recent studies showed that berberine altered microRNAs (miRNAs) expressions. Berberine modulated the expression of miR-21 in multiple myeloma, ovarian cancer and liver cancer (Hu et al., 2013; Liu et al., 2013; Lo et al., 2013) to induce apoptosis, sensitize chemotherapeutic drug and inhibit cell growth. Berberine also upregulated miR-203 in gastric cancer to improve chemotherapeutic response (You et al., 2016) , meanwhile downregulated miR-122 to inhibit the expression of gluconeogenic and lipid metabolism enzymes in hepatoma cells (Wei et al., 2016) . More recently, studies showed that miRNAs are critical in hepatosteatosis. Upregulation of miR-155 was observed in mice fed with methionine-choline-deficient diet which developed liver steatosis while mice with knockout of miR-155 had reduced steatosis (Csak et al., 2015) . Induction of another miRNA miR-132 reduced its target gene transcripts FoxO3, Pten and Sirt1 that were associated with steatosis (Hanin et al., 2017) . In addition, lipid accumulation impaired the biogenesis of miR-206 in fatty livers of dietary obese mice and human hepatocytes. Restoration of miR-206 into the liver of obese mice could strongly inhibit hepatosteatosis (Wu et al., 2017) . Exploration of berberine effect to miRNAs can provide additional evidence in supporting the potential therapeutic effect of berberine against hepatosteatosis and its associated diseases including hepatitis and hepatocellular carcinoma. Here, we studied the effect of berberine to global miRNAs expression in human hepatocytes, and attempted to identify the critical miRNA and its targets that were associated with berberine clinical effects against hepatosteatosis.
Materials and methods

Cell lines and berberine treatment
The human non-tumorigenic, immortalized liver cell line MIHA was kindly provided by Dr J.R. Chowdhury, Albert Einstein College of Medicine, New York. HEK293T and HepG2 cell lines were purchased from American Type Culture Collection (ATCC, University Boulevard Manassas, Virginia, USA). All cell lines were maintained in Dulbecco's Modified Eagle's Media (DMEM) (Thermo Fisher Scientific, Grand Island New York, USA) containing 10% FBS (v/v) (HyClone, GE Healthcare Life Sciences, South Logan, Utah) and 100 units/ml penicillin and 100 μg/ml streptomycin (Thermo Fisher Scientific, Grand Island New York, USA). They were cultured at 37°C in a humidified chamber with 5% CO2. Berberine (Sigma, St. Louis, Missouri, USA) was dissolved in dimethyl sulfoxide (DMSO) (10 mM stock solution), and cells were treated with berberine and its respectively DMSO control at the designated dosages and time points.
Quantitative reverse-transcription PCR (qRT-PCR)
Total RNA from cell cultures were extracted using Trizol (Thermo Fisher Scientific, Carlsbad, California, USA). Measurement of gene expression was performed by locked nucleic acid (LNA) based qRT-PCR. MicroRNA profilings were conducted using microRNA Ready-to-Use PCR, Human panel I+II, V2.M (Exiqon, Vedbaek, Denmark). For mRNA, cDNA was converted from total RNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, California, USA). For microRNA expression level measurement, mirVana™ qRT-PCR miRNA Detection Kit (Applied Biosystems, Foster City, California, USA) was used during validation and candidate miRNAs detection. qRT-PCR was performed by ABI 7900HT Real-Time PCR system using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, California, USA). All assays were performed as described in our previous study .
Promoter luciferase reporter assay
Promoter region of miR-373 was cloned into pGL3 basic vector (Promega Corporation, Madison, Wisconsin, USA) 5′ to the Firefly luciferase gene. Reporter vector and Renilla luciferase vector were cotransfected into HEK293T cells using Lipofectamine 2000 (Thermo Fisher Scientific, Carlsbad, California, USA) for 24 h. Dual-luciferase reporter assay (Promega Corporation, Madison, Wisconsin, USA) was performed according to manufacturer's user manual. Difference in transfection rate between each transfection was normalized by the measurement of Renilla luciferase activity. Relative luciferase activity was determined by 'Firefly luciferase signal/Renilla luciferase signal'. Luciferase activity was measured by using a SpectraMax i3x MultiMode Detection Platform (Molecular Devices, Orleans Drive Sunnyvale, California, USA).
Gene expression microarray analysis
Genome-wide gene expression was measured using The GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix, Thermo Fisher Scientific, Carlsbad, California, USA). A list of differentially expressed genes with fold change larger or equal to 2 was generated. Pathway enrichment analysis was conducted to visualize the pathways affected by berberine treatment.
2.5. miR-373 mimics, inhibitors and small interfering RNAs (siRNAs) transfection miR-373 mimics, miR-373 inhibitors, and siRNAs targeting EGR1 (Shanghai GenePharma Corporation, Shanghai, China) were transfected into cells using DharmaFECT 1 siRNA transfection reagent (Thermo Fisher Scientific, Lafayette, Colorado, USA) according to our previous study .
Western blot
Protein lysates were prepared and quantified following procedures as previous described (Chen et al., 2007) . Proteins were resolved in SDS-polyacrylamide gel and were transferred to PVDF membranes (BioRad, Hercules, California, United States). The membranes were blocked with 5% (w/v) non-fat milk and were incubated with anti-Actin, anti-AKT1, anti-mTOR, anti-RICTOR (Merck Millipore, Billerica, Massachusetts, United States) and anti-phospho-S6K (Immunoway Biotechnology, Plano, Texas, USA) antibodies overnight at 4°C and HRPconjugated anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA) for 1 h. Chemiluminescence signals were developed using LumiGLO® Reagent and Peroxide (Cell Signaling Technology, Danvers, Massachusetts, USA).
Statistical analysis
Statistical tests for data analysis included two-tailed Student's t-test. Data were presented as mean ± S.D. P-values < 0.05 were considered statistically significant.
Results
Berberine upregulated miR-373 in hepatocytes
We firstly determined the efficacious dosage and timepoint of berberine treatment in inducing differential gene expression. As it was reported that LDLR was a direct target induced by berberine (Kong et al., 2004) , we measured the level of LDLR upregulation as a reference to determine effective berberine doses and timepoints in hepatocytes. To do so, we extracted the RNA from these cells after various doses of berberine treatment, and then measured the LDLR mRNA levels by qRT-PCR. To study the effective dosage of berberine, we treated MIHA cells with 10 µM, 20 µM and 100 µM berberine for 24 h. There was a dosage dependent increase of LDLR mRNA levels during the berberine treatment compared to control ( Supplementary Fig. 1 ). We also measured LDLR mRNA levels at various timepoints, and showed that the induction of LDLR was the highest at 16 h ( Supplementary Fig. 2 ). It allowed us to pick the efficacious dosage and timepoint of berberine for : miR-373 expression could be induced at various timepoint ranging from 4 to 16 h. * P-value < 0.05, ** Pvalue < 0.01, *** P-value < 0.001. studying the gene regulatory effect in MIHA cells. We then performed a locked nucleic acid (LNA)-based microRNA profiling using microRNA Ready-to-Use PCR, Human panel I+II, V2.M (Exiqon) in MIHA and HepG2 cells treated with 20 µM berberine and DMSO control for 16 h. A number of miRNAs were differential expressed after berberine treatment in both cell lines (Fig. 1A) . In turn, we validated the profiling in both cell lines using mirVana™ qRT-PCR miRNA Detection Kit, and showed that miR-141, miR-219, miR-186, miR-373 and miR-502-5p were upregulated in MIHA cells, while miR-192, miR-663, miR-373, let7c and miR-502-5p were upregulated in HepG2 cells (Fig. 1B) . Integrated miRNAs pathway analysis was conducted using miRPath to predict the pathways regulated by the altered miRNAs, and showed that critical signaling pathways were affected after berberine treatment (Fig. 1C) . These signalings included PI3K-AKT pathway, MAPK signaling pathway, Wnt signaling pathway, mTOR signaling pathway and insulin signaling pathway. These pathways play different roles in various pathological conditions in human liver including NAFLD, hepatosteatosis and systemic insulin resistance (Liao et al., 2017; Sun et al., 2016; Carpino et al., 2016; Pajvani et al., 2013) . To note, miR-373 was one of the miRNAs commonly upregulated in both cell lines after berberine treatment. In turn, we evaluated the dosage dependent effect of berberine to the miRNAs. We treated MIHA and HepG2 cells with 10 μM and 20 μM berberine for 16 h, and observed that the level of miR-373 was induced in a berberine dosage dependent manner in both MIHA and HepG2 cells (Fig. 1D ). We also treated the cells with 20 μM berberine at 4 h, 8 h and 16 h, and miR-373 expression could be induced at various timepoints (Fig. 1E ). We believed that miR-373 was a specific target induced by berberine in hepatocytes that potentially contributed to the therapeutic effect of berberine.
Berberine transcriptionally induced miR-373 expression
Subsequently, we attempted to study the regulation mode of berberine on miR-373 induction. The promoter region of the miR-373 was cloned into a luciferase reporter pGL3-basic for measuring the promoter activity of miR-373. After transfection of miR-373 luciferase reporter into HEK293T cells, the cells were treated with berberine or DMSO control. Dual-luciferase assay showed that the promoter activity of miR-373 was increased after berberine treatments, and the level of promoter activity was positively correlated to the concentration of berberine treated ( Fig. 2A) . It suggested that berberine transcriptionally induced miR-373 expression. We then measured the primary and precursor forms of miR-373 (pri-miR-373 and pre-miR-373) in both MIHA and HepG2 cells after berberine treatment. qRT-PCR showed that the primiR-373 and pre-miR-373 were induced in MIHA cells as early as 30 min of berberine treatment ( Fig. 2B and C) . qRT-PCR also showed that the pri-miR-373 and pre-miR-373 were induced in HepG2 cells at 4 h and 8 h of berberine treatment respectively ( Fig. 2D and E) . The difference of the induction between MIHA and HepG2 might due to various reasons including difference in drug uptake rate or the difference in endogenous miR-373 level. Nonetheless, we observed the upregulation of pri-miR-373 and pre-miR-373 in both cell lines. Taken together, we showed that berberine treatment on hepatocytes could lead to the upregulation of miR-373 by enhancing the transcription of miR-373 gene and increasing the precursor molecules for the biogenesis of mature miR-373.
Berberine activates miR-373 via EGR1
To study the underlying mechanism for the induction of miR-373 by berberine, we attempted to identify the players that promoted the transcription of miR-373. By bioinformatics, we identified the critical elements within the miR-373 promoter region, and they included Activator Protein 1, Early Growth Response Protein 1 (EGR1) and tumor protein p53 (Fig. 3A) . In parallel, we conducted global gene expression microarray using total RNA extracted from berberine-treated MIHA cells to identify the differential expression of protein-coding genes after berberine treatment. A list of differentially expressed genes was generated after the microarray analysis (Fig. 3B) . Pathway analysis showed that the affected genes played important roles in various pathways associated with cell metabolisms such as glycerolipid metabolism and steroid hormone biosynthesis (Fig. 3C ). Among these differentially expressed genes, we observed that the EGR1 level was upregulated after berberine treatment which matched our bioinformatics prediction. We validated the microarray result by qRT-PCR, and showed that berberine treatment could remarkably induce the expression of EGR1 in MIHA cells (Fig. 3D) . We hypothesized that the induction of miR-373 was a result of EGR1 upregulation during berberine treatment. To prove that the induction of miR-373 by berberine was dependent on EGR1, we study the interactive effect between berberine treatment and EGR1 inhibition in MIHA cells. Inhibition of EGR1 was achieved by transfecting siRNAs targeting EGR1 mRNA in MIHA cells, and the knockdown efficiency was measured by qRT-PCR ( Supplementary Fig. 3 ). For the berberine treatment, cells were treated with either 20 μM berberine or 0.2% DMSO. While berberine treatment could promote the expression of miR-373 in MIHA cells, knockdown of EGR1 by siRNAs could attenuate the induction of miR-373 (Fig. 3E) . It suggested that berberine treatment induced transcriptional factor EGR1 expression, and subsequently transactivated miR-373 expression in hepatocytes. Literatures showed that EGR1 played important roles in lipid metabolism, and several studies demonstrated its anti-hepatosteatosis effects which is also observed as one of the therapeutic effect of berberine .
Berberine reduced AKT-mTOR through inhibition of AKT1
As berberine could promote the expression of EGR1 in hepatocytes and EGR1 was shown to have anti-hepatosteatosis effect, we hypothesized that the induction of miR-373 by EGR1 contributed to the therapeutic effect of berberine on hepatosteatosis. To prove it, we attempted to identify the target of miR-373 that was both regulated by berberine and was implicated in hepatosteatosis. By literature review, we looked up at the genes that were reported to be downregulated after berberine treatment, and then measured their expressions by qRT-PCR in berberine-treated MIHA cells. We showed that the protein kinase AKT1 was downregulated in different doses of berberine, and showed dosage dependent response (Fig. 4A) . AKT1 was also downregulated in 20 µM berberine treatment at various timepoints (Fig. 4B) . Western blotting analysis also showed that berberine treatment could reduce the protein level of AKT1 in both MIHA and HepG2 cells (Fig. 4C) . In parallel, we predicted the potential miRNAs bound to the 3′ untranslated region (3′ UTR) of the genes, and observed the present of miR-373 binding region on AKT1 3′ UTR. It is highly possible that level of AKT1 was downregulated by berberine via the induction of miR-373 in hepatocytes. AKT1 played critical role in PI3K-AKT-mTOR signaling pathway. It was reported that PI3K-AKT-mTOR pathway could activate the expression of p70 S6 kinase (S6K) in liver cells. Study showed that P70 S6 kinase was responsible to the LXRα-dependent lipogenesis (Hwahng et al., 2009) , and activation of S6 kinase could promote hepatosteatosis and systemic insulin resistance (Bae et al., 2012) . Inhibition of AKT1 in MIHA and HepG2 cells could inhibit the AKT-mTOR pathway activity, as western blotting analysis showed that berberine treatment could reduce the protein level of mTOR and RICTOR in both MIHA and HepG2 cells (Fig. 4D) .
AKT1 was regulated by miR-373
We found that the 3′UTR of protein kinase AKT1 was predicted to have interaction with miR-373. To show that the reduction of AKT1 during berberine treatment was attributed by the induction of miR-373 by berberine, we transfected the inhibitors of miR-373 and mimics of miR-373 into MIHA cells and measured the level of AKT1 by qRT-PCR.
We showed that elevating miR-373 level in MIHA cells by transfecting miR-373 mimics could repress the level of AKT1 (Fig. 5A) . Transfecting miR-373 mimics into HepG2 cells could also reduce the AKT1 mRNA level (Fig. 5B) . Meanwhile, inhibition of miR-373 activity by transfecting miR-373 inhibitors in MIHA cells could upregulate AKT1 expression (Fig. 5C) . Inhibition of miR-373 by overexpressing the antagomiR of miR-373 was conducted through the transduction of lentivirus carrying miR-373 antagomiR transgene in into HepG2 cells. Inhibition of miR-373 could lead to the upregulation of AKT1 in HepG2 (Fig. 5D ).
Western blotting analysis showed that inhibition of miR-373 could increase the protein level of AKT1 in MIHA cells (Fig. 5E ). These evidences suggested that AKT1 level was regulated by miR-373 in hepatocytes.
Berberine treatment downregulated AKT1-S6K pathway through miR-373 induction
To prove that the downregulation of AKT1 during berberine Dual-luciferase assay showed that the promoter activity of miR-373 was increased after 10 μM and 20 μM berberine treatment. qRT-PCR showed that (B): the pri-miR-373 and (C): pre-miR-373 were induced in MIHA cells from 0.5 to 3.5 h of berberine treatment. qRT-PCR also showed that (D): the pri-miR-373 and (E): pre-miR-373 were induced in HepG2 cells at 4 h and 8 h of berberine treatments respectively. * P-value < 0.05, ** P-value < 0.01, *** Pvalue < 0.001. While berberine treatment could promote the expression of miR-373 in MIHA cells, knockdown of EGR1 by siRNAs could attenuate the induction of miR-373. siNC: Negative control of siRNAs. siEGR1: siRNAs targeting EGR1. * P-value < 0.05, *** P-value < 0.001.
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European Journal of Pharmacology 825 (2018) 107-118 treatment was mediated by the induction of miR-373, we performed a rescue experiment to study the interactive role between berberine and miR-373. Firstly, berberine treatment could readily reduce the level of AKT1 in MIHA cells. The transfection of miR-373 inhibitors could attenuate the inhibition effect of berberine to AKT1 (Fig. 6A) . It suggested that miR-373 was the mediator of berberine to inhibit AKT1 in hepatocytes. We then study the potential synergetic effect of berberine and miR-373 overexpression in MIHA cells. We showed that overexpression of miR-373 by transfecting miR-373 mimics into MIHA cells could further repress the level of AKT1 (Fig. 6B) . Furthermore, we showed that inhibition of EGR1 by transient transfection of siRNAs could attenuate the inhibition effect of AKT1 by berberine treatment (Fig. 6C) . It showed that berberine regulated the activity of AKT1 pathway through the upregulation of miR-373 expression, in which the induction Inhibition of AKT1 in MIHA and HepG2 cells could inhibit the AKT-mTOR pathway activity, as Western blotting analysis showed that berberine treatment could also reduce the protein level of mTOR and RICTOR in both MIHA and HepG2 cells. * P-value < 0.05, *** P-value < 0.001.
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of miR-373 transcription was promoted by increased expression of EGR1. Lastly, we showed that miR-373 played a role in hepatosteatosis and systemic insulin resistance, as transient increase of miR-373 level in MIHA cells could reduce the level of phosphorylated S6K kinase (Fig. 6D) . Taken together, we showed that berberine treatment could induce the expression level of miR-373, and miR-373 then target AKT1 mRNA, leading to the reduction of AKT1 level. Depletion of AKT1 led to a reduction of AKT1-mTOR pathway activity, and subsequently inhibited the level of phosphorylated S6K kinase in hepatocytes which alleviated the effect of S6K-mediated hepatosteatosis and systemic insulin resistance.
Discussion
Berberine exhibits therapeutic effects to various diseases including NAFLD, hepatosteatosis, steatohepatitis, and inflammation (Zhang et al., , 2008 Kong et al., 2009; Chang et al., 2010; Guo et al., 2016) . Its therapeutic effects are attributed to its ability to regulate Western blotting analysis showed that inhibition of miR-373 could increase the protein level of AKT1 in MIHA cells. NC mimic: negative control of miR-373 mimics; NC inhibitor: negative control of miR-373 inhibitor; shSCR: negative control of antagomir; Anta-373: antagomir of miR-373-3p. * P-value < 0.05, ** P-value < 0.01, *** P-value < 0.001. mRNA and protein expressions. Berberine could also alter the expression of miRNAs in cancer cells to give anti-cancer effects (Lo et al., 2013; You et al., 2016; Wei et al., 2016) . However, the effects of berberine-regulated miRNAs on other liver diseases are largely unexplored. Only recently, the role of miRNA in abnormal lipid deposition is catching increasing attention. MiR-367 promoted liver steatosis through repressing TBL1 in obese mice . Deficiency of miR-150 ameliorated hepatosteatosis and insulin resistance in NAFLD by targeting CASP8 and FADD-like apoptotic regulator (Zhuge and Li, 2017) . On the other hand, miRNA such as miR-155 may protect patients with diabetes from hepatic steatosis (Miller et al., 2013) . MiR-206 is another miRNA that is potent in inhibiting lipid production by impairing hepatic lipogenesis (Wu et al., 2017) . Previously, miR-378 is identified to be the inhibitory target of a dietary antioxidant fisetin that protected the mice against hepatosteatosis (Jeon et al., 2013) . We believe that by identifying novel miRNAs and their putative gene targets associated with abnormal hepatic lipid deposition, the underlying mechanism of these diseases could be established and more effective NC inhibitor: negative control of miR-373 inhibitor; NC mimic: negative control of miR-373 mimics; shSCR: negative control of antagomir; Anta-373: antagomir of miR-373-3p; siNC: Negative control of siRNAs; siEGR1: siRNAs targeting EGR1. * P-value < 0.05, ** P-value < 0.01.
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European Journal of Pharmacology 825 (2018) 107-118 therapies against the disease could be developed. In this study, we attempted to identify the miRNAs regulated by berberine in hepatocytes, and characterize their functions in improving hepatosteatosis. We showed that upregulation of miR-373 by berberine could potentially improve hepatosteatosis. In this study, we treated both the non-tumor hepatocyte cell line MIHA and hepatoma cell line HepG2 with berberine. Subsequently, we measured the differential expression of miRNAs and validated that miR-373 was highly upregulated in both cell lines. Previous studies had demonstrated that berberine was capable of regulating the expression of miRNAs (Lo et al., 2013; You et al., 2016; Wei et al., 2016) . miR-373 was a specific target induced by berberine as the expression level of miR-373 changed in a berberine dosage and treatment time dependent manner. The roles of miR-373 are frequently implicated in cancers, but they are poorly studied in other hepatic diseases. Understanding the role of miR-373 in berberine treatment not only provide a novel therapeutic strategy in treating abnormal lipid deposition in liver, but may become the key link between lipid abnormality with other hepatic diseases such as HCC.
Berberine exhibits therapeutic effects on different diseases through the activation of specific signaling pathways. One of the known signaling pathways regulated by berberine was AKT signaling pathway. Berberine protects homocysteic acid-induced neuronal cell death through the modulation of AKT pathway (Chen et al., 2015) . Berberine inhibited AKT-mTOR pathway in gastric cancer cells to reduce in vivo cancer cell growth (Yi et al., 2015) . In breast cancer cells, treatment of berberine could reduce the mRNA level of AKT and in turn inhibit both AKT and phosphor-AKT protein levels (Kuo et al., 2012) . However, the underlying mechanism on how berberine inhibited AKT was poorly understood. We dissected the mechanism by showing that downregulation of one of the AKT family member AKT1 was attributed to the induction of miR-373. The 3′ UTR of AKT1 transcript harbours miR-373 binding region, and we proved that AKT1 was the putative target of miR-373 as both its mRNA and protein levels were altered with manipulation of miR-373 level. The regulatory pathway miR-373-AKT1 of berberine might contribute heavily to its therapeutic effect on hepatosteatosis, as we observed an obvious inhibition of the AKT-mTOR-S6K pathway. Studies showed that inhibition or depletion of liver specific S6K could protect against hepatosteatosis and systemic insulin resistance (Bae et al., 2012) . Depletion of S6K could reduce the induction of lipogenic gene expression such as sterol regulatory element binding protein 1c (Yecies et al., 2011) . S6K is a kinase that phosphorylates and activates ribosomal protein S6, and in turn affects protein synthesis. S6K can also induce transactivation of genes through phosphorylation and activation of various transcriptional factors. The transcriptional factor LXRα was reported to be phosphorylated by S6K which induced lipogenic genes transactivation (Hwahng et al., 2009 ). This study also showed that activation of AMPK by dithiolethiones could lead to the inhibition of mTOR-S6K activity which resulted in reduced lipogenesis (Hwahng et al., 2009) . Activity of S6K is largely dependent on the complex mTORC1 and the upstream signaling including AKT signaling (Park et al., 2002) . The specific induction of miR-373 by berberine was critical in inhibiting the phosphorylated S6K level in hepatocytes via the targeting AKT1 and inactivation of AKT1/mTOR pathway, and potentially contributed to the therapeutic effects of berberine against hepatosteatosis.
We showed that upregulation of EGR1 was the underlying mechanism of the induction of miR-373 by berberine. EGR1 is also implicated in hepatosteatosis, and reports suggested that EGR1 elicited anti-adipogenic effect. Pharmacological treatment of FGF21 could induce the expression of EGR1 and lower serum free fatty acids (Fisher et al., 2010) . High fat diet, that was associated with insulin resistance and hepatosteatosis in mice, could impair the induction of EGR1 expression . Re-expression of EGR1 was associated with anti-diabetes and anti-hepatosteatosis effects. As such, it is possible that transcriptional activation of miR-373 by EGR1 partially attributed to the therapeutic effect against hepatosteatosis.
Previous studies mostly acquired hepatoma cell line HepG2 as the hepatic cell model to study the effect of berberine to hepatosteatosis (Kou et al., 2016; Wang et al., 2016) . However, given the malignant status of HepG2 cells (López-Terrada et al., 2009) , the studies might not accurately reflect the normal physiological response of berberine treatment to hepatocytes. Here, we used the non-tumor hepatic MIHA cell as the model to study the effect of berberine, which is in theory a more appropriate hepatic model to profile gene expression affected by berberine. To study a specific condition, it is highly beneficial to employ a model closely related as the effect of berberine could be highly dependent on the cell context. For instance, a recent report studying the effect of berberine on ischemia-induced angiogenesis in mice heart, they treated the endothelial cells with berberine and subsequently observed an upregulation of miR-29b (Zhu et al., 2017) . They showed that upregulation of miR-29b could promote the phosphorylation of AKT in endothelial cells, while we showed that berberine could reduce the level of AKT1 by upregulation of miR-373 in MIHA cells. Consistent to our study, a recent report also demonstrated the potential therapeutic effect against hepatosteatosis by inhibiting AKT. The study showed that deletion of AKT2 in null mice could attenuate steatosis via the abrogation of AKT2 dependent pathway (Debebe et al., 2017) . It demonstrated the importance of selecting an appropriate model in order to identify the specific molecular events induced by berberine. Therefore, our approach to characterize the miRNA identified from berberinetreated MIHA cell would be more appropriate than selecting miRNAs solely using malignant cells treated with berberine (Wei et al., 2016) .
In our study, we mainly treated the hepatocytes with 10 μM or 20 μM berberine. According to the pharmacokinetic study of berberine in rats, berberine and its bioactive metabolites were highly concentrated in liver tissue which explained its huge effect on hepatocytes. The levels of berberine together with its metabolites in liver were3 000 ng/ml × h when the rat was orally administrated with 200 mg/kg berberine (Tan et al., 2013) . In our study, the berberine dose used was 20 μM which was equal to about 8000 ng/ml of berberine (~2-3 fold of the rat liver tissue), while 10uM berberine resembled the level of berberine in rat liver. To note, we showed that 10 μM of berberine was able to promote miR-373 expression and inhibit AKT1. As such, the doses adapted in this study were theoretically achievable in therapeutic dose.
In this study, we mainly focused on identifying the molecular pathway critical in the formation of hepatosteatosis that was affected during berberine treatment, which provided the underlying mechanism explaining the therapeutic effect of berberine against abnormal lipid deposition in liver. However, the therapeutic efficacy of manipulating miR-373 against hepatosteatosis was not explored. Given the specific upregulation of miR-373 during berberine treatment in hepatocytes together with the potent inhibition of AKT signaling by miR-373, the manipulating miR-373 in human hepatocytes is a promising strategy in treating hepatosteatosis. Currently, there are many strategies to manipulate miRNAs in treating diseases, including the administration of miRNA mimics to replenish the suboptimal miRNA levels. Research on effective delivery of the miRNA mimics could prompt the development of miRNA replenishment treatment. Studies also demonstrated that many drugs showed "off-target effect" to modulate miRNAs level that contributed to their therapeutic effects against diseases such as vascular and cardiac diseases (Athyros et al., 2016) . Identification of available drugs that could modulate miRNAs critical in the development of hepatosteatosis is also a promising strategy. Research can also be conducted to study the concomitant effect in treating hepatosteatosis with concomitant manipulating the expression of miRNAs such as overexpression of miR-373.
Conclusion
In summary, we showed that berberine treatment could inhibit AKT1-mTOR-S6K signaling activity through induction of miR-373 via EGR1 activation in hepatocytes. As AKT-mTOR-S6K signaling pathway plays important role in promoting hepatosteatosis, this study provided the basis and potential underlying mechanism to support the therapeutic effect of berberine against hepatosteatosis. The therapeutic effect of manipulating miR-373 in treating hepatosteatosis is worth further investigation.
